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Abstract
Roughened surfaces are increasingly being used for dental 
implant applications as the enlarged contact area improves 
bone cell anchorage, thereby facilitating osseointegration. 
However, the additional surface area also entails a 
higher risk for the development of biofilm associated 
infections, an etiologic factor for many dental ailments, 
including peri-implantitis. To overcome this problem, we 
designed a dental implant composed of a porous titanium-
silica (Ti/SiO2) composite material and containing an 
internal reservoir that can be loaded with antimicrobial 
compounds. The composite material consists of a sol-gel 
derived mesoporous SiO2 diffusion barrier integrated in a 
macroporous Ti load-bearing structure obtained by powder 
metallurgical processing. The antimicrobial compounds 
can diffuse through the porous implant walls, thereby 
reducing microbial biofilm formation on the implant 
surface. A continuous release of µM concentrations of 
chlorhexidine through the Ti/SiO2 composite material 
was measured, without initial burst effect, over at least 
10 days and using a 5 mM chlorhexidine solution in the 
implant reservoir. Metabolic staining, CFU counting and 
visualisation by scanning electron microscopy confirmed 
that Streptococcus mutans biofilm formation on the 
implant surface was almost completely prevented due to 
chlorhexidine release (preventive setup). Moreover, we 
demonstrated efficacy of released chlorhexidine against 
mature Streptococcus mutans biofilms (curative setup). In 
conclusion, we provide a proof of concept of the sustained 
release of chlorhexidine, one of the most widely used oral 
antiseptics, through the Ti/SiO2 material thereby preventing 
and eradicating biofilm formation on the surface of the 
dental implant. In principle, our flexible design allows for 
the use of any bioactive compound, as discussed.
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Introduction
The increased use of implanted medical devices in 
humans (a trend which is likely to continue with aging 
populations) largely explains the rise in infectious implant 
complications. Foreign organisms can be introduced into 
the body during implant installation and the implant surface 
often forms an ideal substrate for adhesion of microbial 
cells, the initial phase of biofilm formation (Busscher et 
al., 2010; Donelli and Vuotto, 2014; Ribeiro et al., 2012). 
Peri-implant infections can also occur in later phases of 
implant therapy. In the case of dental implants for example, 
infections can occur by bacterial contamination (e.g. due 
to poor oral hygiene or soft tissue complications) or be 
induced by other factors (e.g. because of remaining of 
crown fixation cement). A higher prevalence of peri-
implantitis has been identified for patients with presence 
or history of periodontal disease and for smokers 
(Marcantonio et al., 2015).
 The emergence of dental implants has introduced such 
artificial surfaces on which oral bacteria can form biofilms 
within the oral cavity (Belibasakis et al., 2015). These 
biofilms can then trigger infection and inflammation of the 
peri-implant tissue (i.e. peri-implantitis), leading to chronic 
infections and progressive peri-implant bone loss in a 
number of oral surgery patients. Moreover, rough implant 
surfaces, which were introduced in the dental market in 
order to improve osseointegration (Bencharit et al., 2014; 
Taniguchi et al., 2015; Yuan et al., 2014), are thought to 
facilitate biofilm formation as the total surface area is 
increased and ‘protected’ areas are provided (Belibasakis et 
al., 2015; Braem et al., 2014; Subramani et al., 2009). Still, 
there is limited and contradictory evidence on the impact 
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of implant surface characteristics on peri-implantitis. 
While several studies reported a positive influence of 
smooth surfaces on peri-implant health (Esposito et al., 
2005; Yuan et al., 2014), others failed to find a correlation 
between the type of implant surface and marginal bone loss 
(de Freitas et al., 2011; Nicu et al., 2012; do Prado et al., 
2013). Nevertheless, oral biofilm formation seems to be 
a defining factor for the success or the failure of a dental 
implant (Subramani et al., 2009) and the prevention and/
or elimination of biofilms at the implant surface is the key 
to tackling peri-implant infections.
 In the case of established biofilms, surgical intervention 
is often required, highlighting the need for new strategies 
to prevent biofilm formation on the implant surface. One 
strategy is the development of implant substrates that can 
resist biofilm formation by microbial pathogens. This can 
be acquired by physical or chemical material treatments 
and/or introduction of antimicrobial agents on the material 
surface. Newly developed antimicrobial surfaces can 
largely be classified as anti-biofouling, resisting or 
preventing microbial attachment, and/or bactericidal, 
killing microbial cells upon contact (Hasan et al., 2013). 
This is usually achieved by applying surface coatings 
of either intrinsically anti-adhesive materials (passive 
coatings) or antimicrobial releasing carrier materials 
(active coatings) or by modifying the implant surface by 
altering the surface topography or the surface chemistry 
(Campoccia et al., 2013; Hasan et al., 2013).
 However, these innovative approaches can also entail 
important drawbacks such as the fragility of such anti-
infective surfaces with respect to the mechanical load 
during dental implant function and the limited effectiveness 
of release coatings due to the short timeframe following 
implantation during which therapeutic concentrations 
of antimicrobials are released (Hickok and Shapiro, 
2012). With this in mind, a novel disk-shaped implant 
material was developed combining the high strength of a 
macroporous Ti structure and the drug-release functionality 
of mesoporous SiO2, enabling a continuous diffusion of 
bioactive compounds from the feed side to the release 
side (Braem et al., 2015). In the current study, we aim to 
realise a proof of concept for the application of this Ti/
SiO2 composite material for a novel dental implant design 
featuring an internal reservoir which can be (re)loaded with 
antimicrobial compounds. It is hypothesised that diffusion 
of antimicrobial compounds through the bulk of the 
implant from the refillable reservoir can establish a stable 
continuous release without burst effects over a prolonged 
period of time, effectively preventing biofilm formation 
during a longer timeframe. Chlorhexidine was selected as 
antimicrobial agent in this study, as it is one of the most 
commonly used and best documented antimicrobials in 
dentistry. It is available in different forms (mouthwash, 
gel, aerosol, spray and disks) and is considered to be 
an effective chemical complement to tooth brushing 
and flossing (Varoni et al., 2012). The antimicrobial 
effectiveness of the released chlorhexidine was evaluated 
using the oral bacterial pathogen Streptococcus mutans (S. 
mutans).
Materials and Methods
Composite Ti/SiO2 disk and implant production
Macroporous Ti disks (Ø 12.2 mm, h = 1.3 mm) were 
prepared by powder metallurgy. Ti (grade S < 8 µm, 
Rockwood Lithium, Frankfurt, Germany) and TiH2 starting 
powders (grade VM, Rockwood Lithium, Frankfurt, 
Germany) were mixed under argon in a 90:10 molar 
ratio using a multidirectional mixer (Turbula T2C, WAB, 
Muttenz, Switzerland) for 24 h. After powder compaction 
by die pressing at 50 kN, the disks were stepwise 
dehydrogenated [heating at 5 °C/min to 450 °C (1 h dwell 
time), at 2 °C/min to 550 °C (1 h dwell time), at 2 °C/min 
to 650 °C (1 h dwell time)] and sintered at 850 °C for 5 min 
in a high vacuum furnace (10-6 mbar). For the production of 
high-strength Ti dental implants, the processing route was 
slightly modified in order to obtain cylinders of sufficient 
length. The starting powder mixture was inserted in 
polymer sleeves (Ø 4 mm prepared by hot dipping; Crocell 
Super SH25, Lambert Products, Waremme, Belgium) and 
compacted by cold isostatic pressing at 3000 bar. The 
resulting cylinders were then stepwise dehydrogenated 
and consolidated as described above. Sintered cylinders 
were machined to the final shape using a CNC milling 
device (TM1, HAAS) applying hard-metal cutting tools 
and drill bits (DIXI polytool, Le Locle, Switzerland) at high 
speed. After machining, implants were decontaminated by 
ultrasonic cleaning in ethanol and acetone for 15 min each 
and rinsing in distilled water. In order to remove metal 
debris and restore the original highly interconnective pore 
structure as required for mass transport through the bulk 
of the material, acid etching was performed in a 1.5 M 
HF (40 %, Sigma-Aldrich, Saint Louis, MO, USA) and 
4.5 M HNO3 (65 %, Chem-Lab, Zedelgem, Belgium) 
aqueous solution for 5 s. After neutralisation with boric 
acid (Fisher Scientific, Illkirch, France) and extensive 
rinsing in distilled water, the samples were cleaned using a 
mixture of ethanol and isopropanol and stored until further 
use. A representative number of implants was analysed by 
scanning electron microscopy (SEM; Nova NanoSEM 450, 
FEI, Zaventem, Belgium) using backscattered imaging 
and associated energy dispersive X-ray spectroscopy 
(EDX, EDAX, Tilburg, The Netherlands) to check for 
organic residue in order to confirm that the samples were 
sufficiently clean.
 Integration of the mesoporous SiO2 diffusion barrier 
was done by sol-gel synthesis. A mixture (1:1 volume) 
of a colloidal SiO2 suspension (Ludox® HS-40, Sigma-
Aldrich, Saint Louis, MO, USA) and an aqueous 0.055 M 
HCl (37 %, Chem-Lab, Zedelgem, Belgium) solution was 
magnetically stirred for 10 min. Using an in-house designed 
sample holder, this sol was injected through the disks or 
through the internal reservoir of the dental implants using 
a high pressure pump (880-PU, Jasco, Easton, MD, USA) 
until the sol could be observed on the outside, to ensure 
the complete sealing of the internal reservoir from the 
implant surroundings. Samples were aged overnight at 
60 °C followed by a heat treatment at 225 °C in air for 6 h 
(1 °C/min heating rate, RHF 1200, Carbolite Furnaces, 
Aartselaar, Belgium) in order to decompose surfactant 
templates (calcination).
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Implant design and characterisation
The design of the dental implants is presented in Fig. 1. It 
was designed to comprise a one piece implant/abutment 
configuration (Ø 3.5 mm, 8 mm intraosseous length, 
3 mm abutment length) for one step surgical installation 
and immediate restoration without the need of a second 
surgery for abutment connection. Moreover, an internal 
reservoir (Ø 1.6 mm, 8 mm of depth) was incorporated 
in the design for customised drug solution storage 
allowing prolonged release of antimicrobial compounds 
through the mesoporous Ti/SiO2 to the implant surface 
and surroundings. The intraosseous part consists of a 
M3.5 double lead thread, while the abutment is featured 
with an external hex connection (hexagonal diameter 
3.2 mm). To improve the ease of insertion and to avoid 
stress concentrations at the implant apex, the apex is 
slightly rounded (R0.5 mm). A stainless steel cover screw 
(M2 × 2.25) for flexible refilling of the internal reservoir is 
equipped with a conical surface mating the 2° countersink 
in the implant abutment in order to provide a sealing surface 
that effectively prevents leakage of the drug solution to the 
oral cavity and vice versa. A representative number of 
polished cross-sections of Ti dental implants, before and 
after incorporation of the mesoporous SiO2 diffusion 
barrier, were examined by SEM and EDX, in order to 
confirm that the SiO2 phase was uniformly distributed into 
the Ti macropores in a consistent way. Pore characteristics 
of the porous Ti dental implants after machining and acid 
etching were measured by mercury intrusion porosimetry 
(MIP, AutoPore IV 9500, Micromeretics, Norcross, GA, 
USA). Characterisation of the mesoporous SiO2 diffusion 
barrier was done by nitrogen adsorption/desorption at 
˗196 °C (Autosorb 1, Quantachrome, Boynton Beach, FL, 
USA) using the Brunauer–Emmett–Teller (BET) method 
and the Density Functional Theory (DFT) method on the 
adsorption branch of the isotherm to determine the specific 
surface area and the pore size distribution, respectively. 
As pre-treatment to remove adsorbed contaminants, the 
samples were evacuated at 200 °C for 12 h.
Strain and chemicals for release experiments
The S. mutans strain Clarke, originally isolated from dental 
caries (Clarke, 1924), was grown routinely on tryptic 
soy broth (TSB) agar plates (Becton Dickinson Benelux, 
Erembodegem, Belgium) at 37 °C for 2 d. Overnight 
cultures were grown in liquid TSB medium.
 Stock solutions of chlorhexidine diacetate salt hydrate 
(Sigma-Aldrich, Saint Louis, MO, USA) were prepared 
in Milli-Q water (Merck Millipore, Overijse, Belgium). 
Artificial gingival crevicular fluid (GCF medium) 
comprised 40 % human serum and 60 % RPMI medium 
[RPMI 1640 (pH 7.0) with L-glutamine and without 
Fig. 1. Conceptual design for a dental implant enabling a sustained drug release. The one-piece implant/abutment 
configuration is made out of a mesoporous Ti/SiO2 composite material allowing diffusion of drug molecules from an 
internal reservoir to the implant surface and surroundings. A cover screw allows easy refilling of the reservoir while 
the conical seal system prevents leakage of the drug solution to the oral cavity.
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sodium bicarbonate buffered with MOPS (all Sigma-
Aldrich, Saint Louis, MO, USA)]. The GCF medium was 
supplemented with 0.5 μg/mL menadione and 5.0 μg/
mL hemin (both Sigma-Aldrich, Saint Louis, MO, USA) 
as described previously (Dalwai et al., 2006). The BHI 
(brain-heart infusion) medium (Becton Dickinson Benelux, 
Erembodegem, Belgium) was supplemented with 3 % 
sucrose (VWR International, Radnor, PA, USA) for S. 
mutans biofilm growth (Junka et al., 2015). Phosphate 
buffered saline (PBS) comprised 8 g/L NaCl, 0.2 g/L KCl, 
1.44 g/L Na2HPO4 and 0.24 g/L KH2PO4 (pH 7.4; all VWR 
International, Radnor, PA, USA).
Chlorhexidine Ti/SiO2 disk release experiments
Release experiments using chlorhexidine and the Ti/SiO2 
composite material shaped in disks were performed in 
our previously developed in vitro test tool (Braem et al., 
2015) with slight alterations which are described here 
(Fig. 2). Solutions based on Milli-Q water containing 
different concentrations of chlorhexidine (0, 0.1, 0.25 
and 1 mM) (termed feed), were supplied to 12-well plates 
(1.4 mL/well, 5 wells/condition). Ti/SiO2 disks sealed into 
polystyrene cups were decontaminated with 100 % ethanol 
(VWR International, Radnor, PA, USA) and dried under 
sterile conditions. Sterile disks were placed in the wells 
of the 12-well plate, thereby assuring contact between 
disk and feed solution. On the release side of the Ti/SiO2 
disk, we administered 300 μL GCF medium, mimicking 
natural gingival crevicular fluid (Dalwai et al., 2006), a 
fluid that is present in the tight anatomical cavity (the so-
called periodontal pocket) formed between tooth or implant 
and periodontal mucosa. Next, the plates were placed in 
a humidified box to avoid evaporation. The GCF release 
medium was replaced each 2 d to maintain sink conditions. 
Chlorhexidine release at 37 °C from the feed side to the 
release side of the Ti/SiO2 disk was measured in 100 μL 
of the release medium by UV spectrophotometry [in UV 
Star microplates (Greiner Bio-One GmbH, Frickenhausen, 
Germany) with a Synergy Mx multi-mode microplate 
reader (Biotek, Winooski, VT, USA)]. Absorbance levels 
were corrected for background absorbance by subtracting 
the absorbance level of GCF medium recovered from 
control Ti/SiO2 disks (blank feed solution). A series of 
solutions containing 6.25-200 μM chlorhexidine in GCF 
medium were prepared fresh for each day of measurement, 
in the original GCF medium that was used for the release 
experiment, to develop a calibration curve. The UV 
absorbance of 100 µL of each suspension was measured, 
confirming a linear relationship between absorbance at 
255 nm and chlorhexidine concentration over the entire 
Fig. 2. Schematic representation of the experimental setup of chlorhexidine release experiments and biofilm prevention 
using Ti/SiO2 disks or implants. The Ti/SiO2 material [grey disk or implant (upper and lower part, respectively)] 
is placed in its respective container. Chlorhexidine or control solutions (dark blue) and GCF medium (light blue) 
are administered to feed and release compartments of both settings, respectively. The spontaneous diffusion of 
chlorhexidine from feed to release side is measured each 2 d using UV spectrophotometry. After 10 d, the GCF 
release medium is replaced with BHI medium (pink) containing approximately 2 × 106 S. mutans cells/mL (green 
dots) to allow bacterial biofilm formation on the implant material (biofilm prevention). After 72 h, biofilm formation 
is quantified using metabolic staining and CFU counting or visualised by SEM imaging.
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concentration range that was tested (R2 = 0.96-0.98). We 
performed two experiments using two or three independent 
Ti/SiO2 disks in each experiment (n = 5).
 To get an indication of the diffusion regime, assuming 
that the release of chlorhexidine is governed by Fickian 
diffusion, an estimate of the order of magnitude of the 
apparent diffusivity was calculated. Fick’s first law was 
applied based on the obtained release data and dimensions 
of the release system (note that the macropores which 
contain the SiO2 phase only take up 30 % of the total 
surface area of the disks) and assuming sink conditions 
(since the release medium was regularly refreshed) and a 
path length equal to the thickness of the disks. The value 
presented is the mean ± SD.
Ti/SiO2 disk biofilm prevention experiment 
After 10 d of chlorhexidine release through the Ti/SiO2 
disks, the GCF release medium was replaced by 300 μL 
BHI medium containing approximately 2 × 106 S. mutans 
cells/mL (Fig. 2). Biofilms of S. mutans were allowed to 
grow on the release side of the Ti/SiO2 disks for 72 h at 
37 °C (renewal of BHI after 48 h), washed with PBS and 
quantified with the viability dye CellTiter-Blue® (CTB, 
Promega, Madison, WI, USA) by adding 300 µL CTB 
diluted 1/10 in PBS to each well. After 2 h of incubation 
in the dark at 37 °C, fluorescence was measured with 
a fluorescence spectrometer (Synergy Mx multi-mode 
microplate reader (Biotek, Winooski, VT, USA) at 
an excitation wavelength of 535 nm and an emission 
wavelength of 590 nm. Fluorescence values of the samples 
were corrected by subtracting the average fluorescence 
value of CTB of uninoculated disks (blank). Percentage of 
metabolically active biofilm cells was calculated relative to 
the control treatment (blank feed solution). We performed 
two experiments using two or three independent Ti/SiO2 
disks in each experiment (n = 5). Results were analysed 
for statistical significance by one-way ANOVA and 
Bonferroni’s correction for multiple testing.
 S. mutans biofilms grown on control Ti/SiO2 disks 
and on Ti/SiO2 disks placed in 1 mM chlorhexidine feed 
solution were visualised by SEM. Prior to SEM analysis, 
samples were carefully washed in PBS to remove non-
adherent cells and fixed with glutaraldehyde [2.5 % in a 
cacodylate buffer (0.1 M, pH 7.4); both Sigma-Aldrich, 
Saint Louis, MO, USA] for 30 min and rinsed 3 times 
with PBS, followed by dehydration in a series of ethanol 
washes (30, 50, 70, 90 and 100 % ethanol for 20 min each). 
Afterwards samples were dried and coated with an Au-Pd 
layer using a sputtering device (Edwards S150) in order to 
produce a thin conductive film on the surface. SEM was 
operated at standard high-vacuum settings at 5 mm working 
distance and 10 keV accelerating voltage. For samples 
containing large amounts of organic (biofilm) material at 
the surface, low-energy imaging using beam deceleration 
was performed by applying a stage (and sample) bias field, 
resulting in an effective landing energy of 5 keV.
Ti/SiO2 disk curative biofilm experiment
Biofilms of S. mutans were allowed to grow on the release 
side of the Ti/SiO2 disks by adding 300 μL BHI medium 
containing approximately 2 × 106 S. mutans cells/mL. 
After incubation for 72 h at 37 °C (renewal of BHI after 
48 h), 1.4 mL of chlorhexidine (0.25 mM) or blank control 
solution was added to the feed compartment. Two days 
later, biofilms were washed with PBS and quantified with 
CTB, as described above. Moreover, the amount of colony 
forming units (CFUs) was determined in biofilms grown 
on control and chlorhexidine-releasing implants. To this 
end, the disks were washed with PBS, vortexed vigorously 
for 1 min, sonicated for 10 min at 45,000 Hz (71.4 W/L) 
in a water bath sonicator (VWR USC 300-T) and vortexed 
again. The detached cells were pelleted by centrifugation 
and washed once more with PBS. A dilution series was 
established in PBS and 100 µL of each dilution was plated 
onto TSA plates. After incubation at 37 °C for at least 24 h, 
the number of CFUs was counted for each condition. The 
experiment was performed using three independent Ti/SiO2 
disks (n = 3).Values are presented as mean ± SEM. Results 
were analysed for statistical significance by unpaired 
student’s t-test.
Chlorhexidine Ti/SiO2 implant release experiments 
and biofilm prevention
Release experiments using chlorhexidine and the Ti/
SiO2 composite material shaped in our novel implant 
design were performed in analogy to the Ti/SiO2 disk 
experiments (Fig. 2). Ti/SiO2 implants and cover screws 
were decontaminated with 100 % ethanol and dried under 
sterile conditions. A solution (termed feed) containing 
chlorhexidine (5 mM) or blank control solution was 
administered to the internal reservoir of the implant 
(10 µL/implant, 3 implants/condition) before closing the 
reservoir with the cover screw. The implant was placed in 
a 0.5 mL Eppendorf tube which contained 90 µL of the 
GCF medium (termed release) and the tube was closed. 
The GCF release medium was replaced after each 2 d to 
maintain sink conditions. Chlorhexidine release at 37 °C 
from the internal reservoir of the implant (feed side) to the 
release side of the Ti/SiO2 implant (containing the GCF 
medium) was measured in 70 μL of the release medium by 
UV spectrophotometry as described above. We performed 
two experiments using three independent Ti/SiO2 disks in 
each experiment (n = 6).
 After 10 d of chlorhexidine release through the Ti/SiO2 
implants, the release medium was replaced by 90 μL BHI 
medium containing approximately 2 × 106 S. mutans cells/
mL (6 implants/condition). Biofilms of S. mutans were 
allowed to grow in the same conditions as described above 
on the release side of the Ti/SiO2 implants. Quantification 
of biofilm metabolic activity was performed as described 
above using 200 µL diluted CTB. Moreover, the amount 
of CFUs was determined as described above.
 To assure that our sonication procedure had no effect 
on the viability of the S. mutans cells, 1 mL of a 10 times 
diluted overnight S. mutans culture was subjected to the 
sonication procedure. A CFU plating experiment confirmed 
no effect of sonication on cell viability (p-value = 0.859 in 
unpaired two-tailed students t-test ;n = 3). Control (without 
sonication) and sonicated cell cultures both contained 
approximately 2 × 107 CFUs. This cell number was chosen 
to represent the number of CFUs present in control biofilms 
formed on the implant surface.
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Minimum (biofilm) inhibitory concentration
Minimum inhibitory concentration (MIC) assays were 
performed in liquid TSB medium. Briefly, overnight 
cultures of bacteria were diluted in fresh medium to a 
final concentration of approximately 5 × 105 cells/mL. 
Next, bacteria were incubated in the presence of a two-
fold dilution series of chlorhexidine. After 24 h of growth 
at 37 °C, bacterial growth was determined by measuring 
the OD595. MIC was interpreted as the lowest antibiotic 
concentration that completely inhibits bacterial growth.
 To assess the anti-biofilm activity of chlorhexidine 
against S. mutans, overnight cultures were diluted 1/200 
in BHI medium and two-fold serial dilutions (150 µL) of 
chlorhexidine in the cell suspensions were prepared in a 
microtiter plate. After 24 h of biofilm formation at 37 °C, 
biofilms were washed with PBS and quantified with 
CTB as described above using 200 µL diluted CTB. The 
lowest concentration of chlorhexidine required to inhibit 
biofilm formation was defined as the biofilm inhibitory 
concentration (BIC).
Cytotoxicity assay
A cytotoxicity test of chlorhexidine was performed on a 
cell type relevant to bone homeostasis. MG63 osteoblast-
like cells, a human osteosarcoma cell line, were obtained 
from ATCC (American Type Culture Collection CRL-
1427, LGC Standards, Molsheim, France). Cells were 
plated in 24-well plates at 2000 cells/cm² in Minimum 
Essential Medium Eagle Alpha Modification (αMEM; 
Sigma-Aldrich, Saint Louis, MO, USA) with 0.292 g/L 
L-glutamine (G7513, Sigma-Aldrich, Saint Louis, MO, 
USA) supplemented with 10 % foetal bovine serum (PAA 
Laboratories GmbH, Pasching, Austria) and 1 % antibiotic-
antimycotic (Gibco 15240, Life Technologies SAS, Saint 
Aubin, France). Cells were maintained overnight at 37 °C 
in a humidified environment with 5 % CO2. The media 
were changed every 48 h.
 At day 2 post seeding, cells were incubated with 
chlorhexidine by adding the compound to the culture 
medium. As a control, a suspension of the same cell 
line under the same conditions, but without chemicals, 
was cultured. Dilution assays started at the maximum 
concentration of 10 µM. Chlorhexidine concentrations 
were freshly prepared at each time point of addition. The 
proliferation of the MG63 cells in the presence or absence 
of chlorhexidine was live investigated by means of a 
resazurin-based reagent (Presto Blue®, Thermo Fischer, 
Breda, The Netherlands) after 2, 4 and 6 d of compound 
addition. The Presto Blue solution (PB) (Life Technologies, 
Ghent, Belgium) was prepared in a proportion of 10 unit 
volumes of medium and 1 unit of reagent. The medium in 
each well was removed and replaced by 0.5 mL of PB. After 
2 h incubation, 2 aliquots of 200 μL were taken from each 
well and transferred to a 96-well plate. The PB solution was 
completely removed from each well and replaced by 1 mL 
of culture medium containing the appropriate chlorhexidine 
concentration. The fluorescent signal was measured with 
an automated microplate fluorimeter (SerColab Systems, 
Merksem, Belgium). The blank value was subtracted from 
the measurement of each group analysed. The experiment 
was performed twice with duplicate measurements.
Results
Chlorhexidine is released in a controlled way through 
Ti/SiO2 composite disks and inhibits S. mutans 
biofilm formation
We used our previously developed in vitro test tool (Braem 
et al., 2015) consisting of the Ti/SiO2 composite material 
shaped into disks (Fig. 2, upper part), as a step-up model 
to assess the release of the antimicrobial compound 
chlorhexidine through the mesoporous material and to 
design the novel implant.
 The 10 d release profile of chlorhexidine through the 
Ti/SiO2 disks, containing different feed concentrations (0.1, 
0.25 and 1 mM), is shown in Fig. 3a. A steady release of 
chlorhexidine was apparent from day 3 after the start of 
the experiment (illustrated by the nearly linear cumulative 
release profile). Feed solutions of 0.1, 0.25 and 1 mM 
chlorhexidine released on average 9, 25 and 99 nmol/cm², 
respectively (corresponding to 33 µM, 89 µM and 359 µM 
in the release medium). Higher chlorhexidine release 
was observed for higher feed concentrations at all time 
points. Moreover, we were able to detect chlorhexidine 
(> 6.25 µM) in the release medium up to 40 d after the 
start of the experiment (using 1 mM chlorhexidine feed 
solution). Based on these release data and assuming that 
the release of chlorhexidine through the SiO2 phase of 
the Ti/SiO2 disks is governed by Fickian diffusion, the 
apparent diffusivity as averaged over the different feed 
concentrations, was estimated to be 2.0 ± 0.1 × 10−11 m2/s.
 Next, we assessed whether the chlorhexidine-releasing 
material could prevent biofilm formation in vitro. Fig. 3b 
shows the metabolic activity of S. mutans biofilm cells 
grown on the release side of Ti/SiO2 disks that were actively 
releasing chlorhexidine. The metabolic activity of biofilm 
cells was significantly decreased (± 99 % reduction) for 
all chlorhexidine feed concentrations as compared to blank 
feed solutions. Bacterial growth on control Ti/SiO2 disks 
and on chlorhexidine-releasing Ti/SiO2 disks (1 mM feed 
solution) was visualised by SEM imaging (Fig. 4). Thick S. 
mutans biofilms were formed only on control Ti/SiO2 disks 
releasing no chlorhexidine. Interconnected mushroom-
shaped micro-colonies, consisting of coccus-shaped S. 
mutans cells, were clearly visible within the biofilm, which 
was spread out over the entire disk surface, covering all 
pores. On the contrary, the open porosity of the Ti/SiO2 
material was still apparent in the chlorhexidine-releasing 
disks, which contain only few attached S. mutans cells 
(Fig. 4). The lowest released chlorhexidine concentration 
(33 µM) was able to kill a S. mutans culture in a normal 
vial of BHI medium in less than 24 h. Inhibition of S. 
mutans by chlorhexidine at the released concentrations 
was expected, since they are well above the MIC (3.2 µM) 
and BIC (1.6 µM) values. It should be noted that the data 
obtained in the preventive Ti/SiO2 disk setup were not 
validated by CFU counting. In this respect, the disk setup 
should be considered as a preliminary tool which enables 
us to (relatively quickly) screen more concentrations and 
compounds (see also Braem et al., 2015). Therefore, only 
metabolic staining and SEM imaging were used to quantify 
and visualise biofilm formation in the preventive setup 
using Ti/SiO2 disks. The following experiments (curative 
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setup and Ti/SiO2 implant experiments) were additionally 
validated by CFU counting.
 To demonstrate that our material was also suitable for 
treatment of established infections, S. mutans biofilms were 
allowed to grow on the release side of the Ti/SiO2 disks 
for 2 d in the absence of chlorhexidine. Administration 
of 0.25 mM chlorhexidine to the feed compartment after 
biofilm maturation significantly reduced the metabolic 
activity (± 98 % reduction) of S. mutans biofilm cells after 
only 2 d of chlorhexidine release (Fig. 3c). CFU counting 
confirmed that the number of retrieved S. mutans biofilm 
cells was significantly reduced from 1.64 ± 1.11 × 106 to 
2.68 ± 1.24 × 104 (p = 0.0197).
Design and characterisation of mesoporous Ti/SiO2 
implants with an internal reservoir
Next, we developed dental implants consisting of the Ti/
SiO2 composite material (Fig. 1). An internal reservoir was 
incorporated in the design for customised drug solution 
storage allowing prolonged release of antimicrobial 
compounds through the mesoporous Ti/SiO2 to the implant 
surface and surroundings.
 Fig. 5a shows a backscattered electron image of a 
cross-sectional detail of the Ti/SiO2 implant near the 
screw thread crest, indicating an angular macroporous Ti 
phase with open surface pores. Indeed, mercury intrusion 
porosimetry of the implant indicated that the open porosity 
amounted 23.0 % while the average interconnecting pore 
window size was 1.4 µm after machining and acid etching 
(Fig. 5c). A representative image of an associated elemental 
(Ti and Si overlay) mapping can be found in Fig. 5b. 
This confirmed the uniform distribution of a SiO2 phase 
throughout the whole Ti pore structure in a consistent 
way. According to nitrogen adsorption measurements, the 
final Ti/SiO2 composite dental implant exhibited a pore 
size distribution ranging from 4 to 10 nm with an average 
mesopore diameter of 5.8 nm and a specific surface area 
of 180.7 m²/g SiO2 (Fig. 5d).
 
Fig. 3. Release of chlorhexidine through Ti/SiO2 disks and associated effect on S. mutans biofilm metabolic 
activity. (a) Cumulative amount of chlorhexidine released through Ti/SiO2 disks in the in vitro test tool for different 
chlorhexidine feed concentrations (measured by UV spectrophotometry at 255 nm). Values are mean ± standard error 
of two independent experiments containing 2-3 repeats (n = 5). (b) Prevention of S. mutans biofilms on Ti/SiO2 disks. 
Values are mean metabolic activity ± standard error of two experiments containing 2-3 repeats (n = 5), measured 
by CTB staining. (c) Eradication of mature S. mutans biofilms on Ti/SiO2 disks. Values are mean metabolic activity 
± standard error of two experiments containing 2-3 repeats (n = 5), measured by CTB staining. The asterisks indicate 
a statistically significant difference in metabolic activity (** p < 0.01; **** p < 0.0001).
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Chlorhexidine is released in a controlled way through 
Ti/SiO2 composite implants and inhibits S. mutans 
biofilm formation
Using the dental implants characterised above, we 
confirmed chlorhexidine release through the Ti/SiO2 
composite material from the internal reservoir (5 mM 
chlorhexidine feed solution, approximately 0.3 %) towards 
the release side (Fig. 6a). Also in this setup, a steady 
release of chlorhexidine could be measured from day 3 
after the start of the experiment (illustrated by the nearly 
linear cumulative release profile). On average 26 nmol/cm² 
chlorhexidine were released from the internal reservoir, 
resulting in an average concentration of 80 µM in the 
release medium.
 The concentration in the release medium depended on 
the volume of the release medium and on the volume of the 
feed solution. Since the ratio of feed volume over release 
volume is 50 times lower in the implant setup, one can 
expect lower release concentrations in the implant setup 
using similar feed concentrations. Indeed, using 5 mM 
chlorhexidine feed solution, the release concentrations 
were remarkably lower in the implant setup (± 80 μM or 
0.005 %) compared to 1 mM feed concentrations in the 
disk setup (resulting in an average release concentration of 
359 µM). The 5 mM feed concentration resulted in release 
concentrations in the implant set up that were comparable 
to release concentrations achieved with 0.1-0.25 mM 
chlorhexidine feed solutions in the disk setup. Significantly 
Fig. 4. SEM image of S. mutans growth on control (left) and chlorhexidine-releasing (right) Ti/SiO2 disks. S. 
mutans was allowed to grow on top of Ti/SiO2 disks following a 10 d release experiment in which control or 1 mM 
chlorhexidine solution were applied in the feed compartment of the in vitro test tool (biofilm prevention). The SEM 
was operated at standard high-vacuum settings at 5 mm working distance. To avoid beam damage of the biofilm on 
control disks, low-energy imaging using beam deceleration was performed by applying a stage (and sample) bias 
field, resulting in an effective landing energy of 5 keV. For chlorhexidine-releasing disks, a 10 keV accelerating 
voltage was used. The formation of mushroom-shaped micro-colonies (red arrows) consisting of S. mutans cells 
(green arrow) is visible on control disks. On the contrary, the open surface porosity is exposed in chlorhexidine-
releasing disks (yellow arrows) which contain only few attached S. mutans cells (blue arrows).
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Fig. 5. Combining macro- and mesoporosity in a Ti/SiO2 composite dental implant. A representative cross-sectional 
detail at the screw thread crest was analysed by SEM using backscattered electron imaging showing (a) macroporous 
Ti (in light grey) and (b) associated elemental mapping confirming the presence of a SiO2 phase (magenta) inside 
the Ti (blue) macropores in a consistent way. (c) Prior to SiO2 infiltration, the macroporous Ti implant has a pore 
window size distribution around 1.4 µm as measured by mercury intrusion porosimetry, while the (d) Ti/SiO2 
composite dental implant presents a mesoporous structure with an average pore size of 5.8 nm as determined by 
nitrogen adsorption measurements.
Fig. 6. Release of chlorhexidine through Ti/SiO2 implant and associated effect on S. mutans metabolic activity. (a) 
Cumulative amount of chlorhexidine released through Ti/SiO2 implants in the in vitro test tool for 5 mM chlorhexidine 
feed concentration (measured by UV spectrophotometry at 255 nm). Values are mean ± standard error (n = 3). (b) 
Metabolic activity of S. mutans biofilms grown for 72 h on Ti/SiO2 implants on the implant surface after 10 d of 
chlorhexidine release. Values are mean ± standard error of two experiments containing 3 repeats (n = 6), measured 
by CTB staining. The asterisks indicate a statistically significant difference in metabolic activity (**** p < 0.0001).
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reduced metabolic activity (± 99 % reduction) of S. mutans 
cells growth on chlorhexidine-releasing implants (5 mM 
feed concentration) was observed compared to S. mutans 
biofilm cells grown on control implants (Fig. 6b).
 We confirmed these observations by CFU counting 
of S. mutans biofilm cells recuperated from the implants. 
Biofilms grown on control Ti/SiO2 implants consisted of 
on average 2.01 ± 0.55 × 107 CFU/implant, whereas no 
CFUs could be retrieved from chlorhexidine-releasing 
implants. This is, however, an underestimation of the 
number of recovered CFUs, since S. mutans cells could 
still be detected on the implant surface after sonication 
(by SEM imaging; data not shown). Nevertheless, it was 
clear that the residual biofilm was considerably larger on 
control Ti/SiO2 implants than on chlorhexidine-releasing 
implants, where only a few remaining cells were observed. 
This indicated that, although sonication was not sufficient 
for a complete removal of established biofilms from the 
implant substrate, CFU counting of recuperated S. mutans 
cells still allowed for a qualitative comparison between the 
different samples. Moreover, the minimal dilution that was 
plated on agar was a 10-fold dilution of the suspension in 
which the biofilm was dissolved, thereby thresholding our 
quantification to 10 CFUs/biofilm.
Chlorhexidine affects the growth potential of 
osteoblast-like cells in a dose-dependent manner
Osteoblasts are key players in the processes of establishment 
and maintenance of implant osseointegration. Therefore, 
in view of the application of chlorhexidine in preventing/
curing peri-implantitis, we examined the cytotoxic effects 
of chlorhexidine on MG63 osteoblast-type cells (Fig. 7). At 
day 2 post-seeding, cells were incubated with chlorhexidine 
by adding different concentrations of the compounds to the 
culture medium. To determine the toxicity of chlorhexidine 
as a function of the various applied concentrations, cell 
proliferation was determined after 2, 4 and 6 d of incubation 
and normalised to the no treatment control on the same 
day. Upon treatment with chlorhexidine up to 1.0 µM, 
human osteoblast-like cells survived and cell proliferation 
was permitted, however cytotoxic behaviour (less than 
70 % proliferation compared to the no treatment control) 
of chlorhexidine towards the osteoblasts was apparent 
for doses above 0.6 µM when cells were treated for more 
than two days.
Discussion
Implant related infections are a serious complication in 
prosthetic surgery. Recently, implants with rough surfaces 
or porous surface coatings are applied for improved 
osseointegration. However, some studies report that the 
increased surface roughness renders the implant more 
susceptible to microbial colonisation and subsequent 
biofilm formation (Belibasakis et al., 2015; Braem et al., 
2014; Subramani et al., 2009). Therefore, the development 
of implant materials or surfaces that combine both the 
ability to improve osseointegration and at the same time 
reduce the infection risk are of interest. The unique implant 
Fig. 7. Effect of chlorhexidine on the viability and growth potential of osteoblast-like cells. MG63 cells were grown 
in 24-well plates in αMEM. At day 2 post-seeding, the cells were incubated with or without chlorhexidine by adding 
the compound or mock treatment to the culture medium. MG63 proliferation profiles were evaluated using Presto Blue 
measurements relative to the no treatment control on the same day, with measurements after 2, 4 and 6 d of compound 
addition. This figure represents two independent biological experiments consisting of two technical repeats each.
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design proposed in this study exposes a rough implant 
surface, while overcoming the reported associated problem 
of increased bacterial growth by controlled release of 
chlorhexidine, which is loaded in the internal reservoir, 
through the Ti/SiO2 composite material.
 The capacity of this Ti/SiO2 composite material to 
transfer the antimicrobial compound chlorhexidine from a 
feed compartment to a release compartment was assessed 
in our in vitro test tool consisting of Ti/SiO2 disks. It was 
demonstrated that chlorhexidine diffuses steadily through 
the mesoporous material over at least 10 d (Fig. 3a) and 
that therapeutically relevant concentrations can be released 
up to 40 d. The kinetic diameter of chlorhexidine having a 
molecular size of ca. 3.4 × 0.7 × 0.6 nm is within the same 
range as the pore size (circa 6 nm) of the SiO2 phase of 
the Ti/SiO2 composite, therefore, the diffusion is governed 
by a configurational regime as indicated by the apparent 
diffusivity in the order of 10-11 m2/s (Verraedt et al., 2010).
 We assessed the activity of the released chlorhexidine 
against S. mutans biofilms, both in a preventive (to 
prevent biofilm formation) and curative setup (to eradicate 
existing biofilms). The choice of the bacterium S. mutans 
in this study should be interpreted as most relevant in the 
preventive set-up – prevention of the biofilm composition 
maturation towards anaerobic species by eradicating 
the preceding aerobic ones. The released chlorhexidine 
was capable of almost completely preventing S. mutans 
biofilm formation on the release side of the Ti/SiO2 disk 
(Fig. 3b and Fig. 4). In a similar setup, the anti-biofilm 
effect of toremifene was previously reported against 
the fungal pathogen Candida albicans (Braem et al., 
2015), demonstrating the broad flexibility of this system 
to act against different biofilm-forming pathogens and 
releasing diverse compounds. Moreover, by adjusting the 
concentration of the feed solution, the amount of released 
compound can be fine-tuned (Fig. 3a). These features 
are unique for drug-releasing implant materials, since 
most implant materials suitable for controlled release of a 
medical drug are preloaded, releasing only one compound 
until depletion. Moreover, using these materials, the drug 
is mainly leached during an initial burst release followed 
by release at sub-therapeutic concentrations, risking 
resistance development (Goodman et al., 2013; Lyndon et 
al., 2014). It should be noted that compounds administered 
into the periodontal pocket are rapidly washed out in vivo 
(Goodson, 2003). To mimic this situation, we refreshed 
the release medium every 2 d to maintain sink conditions. 
GCF flow rates are highly dependent on the disease state 
with higher values with increasing infection status (from 
5 µL/h up to 137 µL/h). Fine-tuning of a continuous flow 
system for this set-up, thereby discriminating between 
healthy persons and patients with intermediate or advanced 
periodontal disease would be most interesting.
 Using the Ti/SiO2 disks, we additionally demonstrated 
activity of released chlorhexidine against mature S. 
mutans biofilms (in a curative setup) (Fig. 3c), both using 
metabolic staining and CFU counting. Consequently, 
treatment of infections occurring in later stages of implant 
therapy is possible as well, by adding the desired agent in 
the reservoir, which is easily accessible. Moreover, this 
confirms that the observed effect is not merely due to a 
surface effect but that the chlorhexidine actively kills S. 
mutans biofilm cells.
 Controlled release of compounds from the internal 
cavity through the implant material is a highly novel 
approach. However, various existing dental implants 
consist of an internal cavity, not for drug release but to 
enable dental surgery. Such cavity allows engaging specific 
surgery tools or screw-retained fixtures, like healing screws, 
abutments or crowns. The concept of combining hollow 
tubular metallic support structures including orifices of 0.2 
up to 1.0 mm with various drug-releasing carrier materials 
inside the internal cavity has been previously suggested, 
among others for percutaneous orthopaedic implants (Clark 
et al., 2008; Gimeno et al., 2015; Park et al., 2014; Perez 
et al., 2011; Santos et al., 2014). The novelty of the current 
design lies in the fact that the mesoporous controlled 
release (SiO2) matrix is incorporated in the (Ti) implant 
walls (Fig. 1 and Fig. 5a, b), rendering the functional 
implant itself a true drug delivery vehicle. Indeed, current 
results indicate that the previously described processing 
route for the Ti/SiO2 composite material (Braem et al., 
2015) was successfully transferred to the proposed dental 
implant design as indicated by the comparable macro- and 
mesoporous characteristics (Fig. 5c, d). The controlled 
release of the molecules applied in the reservoir is governed 
by their diffusion through the mesoporous SiO2 phase. It is 
well known that by controlling the pore morphology and/
or chemistry of SiO2 materials the diffusion (and hence the 
release kinetics) of therapeutic molecules can be fine-tuned 
(Aerts et al., 2010; Bhaskara et al., 2014; Bhattacharyya et 
al., 2014; Santamaria et al., 2014; Verraedt et al., 2010). 
We hypothesise that incorporating a SiO2 material with 
adequate pore characteristics will allow to adapt the system 
for any specific molecule. Moreover, there is no risk for 
bacteria to enter the implant, since the mesopores in the 
Ti/SiO2 are only a few nm in diameter, which is too small 
for bacteria to enter.
 Up to now, the clinical implementation of localised drug 
delivery around dental implants has been limited to the 
application of drug eluting coatings on the implant surface 
or the injection of bioresorbable drug carriers into the peri-
implant pocket (Santos et al., 2014). While coatings are 
fragile and can easily get damaged upon implant insertion 
(Hickok and Shapiro, 2012), drug carrier materials in the 
peri-implant gingival pockets are subject to erosion due 
to masticatory action. With this drug-releasing functional 
dental implant, a more reliable and more homogeneously 
distributed antimicrobial release over the entire implant 
surface area is envisaged and over an extended time period. 
By applying a 5 mM (approximately 0.3 %) chlorhexidine 
feed solution in the implant reservoir, we obtained a steady 
release resulting in on average 80 µM chlorhexidine 
(approximately 0.005 %) in the release medium over at 
least 10 d (Fig. 6a). However, based on the results from 
the extended Ti/SiO2 disk experiment, we also can expect a 
much longer release of active chlorhexidine concentrations 
from the Ti/SiO2 implant.
 Many studies have reported benefits associated with 
chlorhexidine treatment as preventive therapy against 
development of peri-implant disease as adjunct to 
mechanical debridement and basic oral hygiene (Pedrazzi 
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et al., 2014). Notwithstanding its efficacy, evidence is 
increasing that chlorhexidine may have deleterious effects 
on various cell types in vitro (Pucher and Daniel, 1992; 
Cline and Layman, 1992; Mariotti and Rumpf, 1999; 
Giannelli et al. 2008). Given that osteoblasts represent 
the main cell type involved in bone tissue regeneration 
and their function is pivotal for the clinical resolution of 
periodontal and peri-implant defects (Shibli et al., 2006), 
the use of chlorhexidine in periodontal and peri-implant 
complications should not affect the osteoblasts and trouble 
tissue homeostasis and healing. The obtained in vitro data 
confirm the cytotoxicity of chlorhexidine directly applied 
onto osteoblasts when used at concentrations exceeding 
1 µM (approximately 0.00006 %). The direct application of 
chlorhexidine at higher concentrations during regenerative 
therapy for the treatment of peri-implantitis could thus have 
serious toxic effects on alveolar osteoblasts. However, the 
use of chlorhexidine mouthwashes (0.12 %) after implant 
installation is almost routine practice to maintain peri-
implant health. Obviously, the contact is only for a few 
seconds or minutes via mucous membrane in this case. 
Interestingly, patients irrigating with diluted chlorhexidine 
(0.06 %, which is still far above the concentrations released 
in our setup) using a powered oral irrigator with a special 
subgingival irrigating tip showed reduced infection 
symptoms compared to patients rinsing with 0.12 % 
chlorhexidine gluconate once daily and is recommended 
as a valuable adjunct to oral health in patients with dental 
implants (Felo et al., 1997). These results suggest that 
tackling the zone most proximal to the implant results in 
superior health outcome. This is precisely what is aimed 
for with the dental implant presented in this study, as it is 
capable of releasing chlorhexidine directly at the implant 
surface. Moreover, the observed chlorhexidine release 
concentrations of 0.005 % were sufficient to prevent S. 
mutans biofilm growth on the implant surface, suggesting 
that very low doses of an antibacterial compound are 
adequate when administered locally during a limited 
time. Due to the complex setup of the experiments 
it was not feasible to repeat the experiments using a 
lower range of chlorhexidine to determine the critical 
release concentration. However, recalling the reported 
MIC/BIC values of 1-3 µM, we estimate that a few 
µM would suffice, which is comparable to the reported 
cytotoxicity limit. Hence, in follow-up experiments, less 
cytotoxic compounds should additionally be evaluated for 
compatibility with our dental implant release system, for 
which chlorhexidine can serve as benchmark.
 Indeed, our design allows for the insertion of other 
antibacterial compounds in the internal reservoir instead 
of chlorhexidine, such as antibiotics, thereby installing 
a very local antibiotics regimen for a prolonged time at 
the place of potential infections. Such local antibiotic 
dosing regimen, avoiding their systemic use, can be 
very attractive as the latter is associated with antibiotic 
resistance development. Moreover, the design of the Ti/
SiO2 composite dental implant presented in this manuscript 
enables a personalised treatment. Different antimicrobial 
compounds or antibiotics can be applied in the internal 
reservoir depending on the patient’s need. Moreover, 
it is hypothesised that consecutive release of different 
antimicrobial compounds or higher doses of the initial 
compound is possible by refilling the reservoir. This 
might be of interest in cases where the applied drug/dose 
appears to be ineffective. Additionally, simultaneous 
release of multiple compounds is envisaged as well, since 
combination therapy offers several advantages compared 
to single compound treatment of both bacterial and fungal 
biofilm infections (Blackledge et al., 2013; De Cremer et 
al., 2015). Once clinical and radiographic data indicate 
successful implant osseointegration, there is obviously 
no need for continued prophylaxis (preventive setup). If 
signs of peri-implantitis would emerge on osseointegrated 
implants at a later stage, the treatment by reversible, 
controlled release and repeatable drug administration can 
be started and stopped at any time (curative setup).
 In conclusion, we provide a proof of concept of the 
sustained release of an antimicrobial compound from 
an internal reservoir through the Ti/SiO2 material to the 
implant outer surface and surroundings. Release of this 
antimicrobial compound prevents and eradicates microbial 
biofilm formation on the rough implant surface, decreasing 
the risk for development of peri-implant diseases. 
Responding to the current need for more personalised 
treatments, our flexible implant design allows for the 
use of a broad range of antimicrobial compounds (alone 
or in combination) and fine-tuning of the concentration 
at which these are released will depend on the patient’s 
need. This study focuses on dental implant applications, 
but the concept could, in principle, be translated to any 
percutaneous implant that can incorporate an internal 
reservoir, such as percutaneous fixation devices, as long 
as this does not compromise the mechanical strength of 
such load-bearing devices.
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Discussion with Reviewer
Llinos Harris: How effective is the system on the other 
bacteria that are commonly present in the mouth? Is it 
possible that the eradication of S. mutans could lead to 
other species flourishing and causing infections?
Authors: Chlorhexidine is known to be a broad-spectrum 
biocide effective against Gram-positive bacteria, Gram-
negative bacteria and fungi. To show the effectiveness of 
our system, we have performed additional experiments and 
demonstrated biofilm-preventing activity of chlorhexidine 
released through Ti/SiO2 disks against Candida albicans 
biofilms, a yeast species known to be involved in dental 
infections (Fig. 8).
Llinos Harris: Do the authors know what would happen 
to the osteoblasts if exposed to the initial burst release 
observed in the first 3 d?
Authors: We have assessed release kinetics of chlorhexidine 
(Fig. 3a) and we described a steady release of chlorhexidine 
from day 3 without initial burst (resulting in mean 
chlorhexidine release of 9 nmol/cm²) for the lowest feed 
concentration (0.1 µM chlorhexidine). In our set-up, this 
corresponds to 33 µM chlorhexidine – a dose with in vitro 
toxicity to osteoblasts. However, it should be noted that 
compounds administered into the periodontal pocket are 
rapidly washed out in vivo (Goodson, 2003). Therefore we 
anticipate that in vivo chlorhexidine release is gradually 
cleared by the surrounding tissue, resulting in lower net 
chlorhexidine concentrations. Hence, it is very difficult 
to predict in vivo toxicity associated with chlorhexidine 
release from our device based on the current in vitro data. 
As a consequence, the data from this study have to be seen 
in a broader context, namely as a proof of concept, which 
can be extended to the use of any bioactive, potentially 
less toxic, compound.
Britt Wildermann: Can you make any assumption 
regarding the effect of cells growing on the implant and 
the release kinetics. Due to the fact that the implant should 
be integrated, the pores might be filled/covered by cells. 
Would this then stop the release and hinder the envisioned 
use to cure a late infection?
Authors: At present, we have no data on the effect of 
osteoblast growth on the material and potential clogging 
of the mesopores, thereby hindering release of the 
antimicrobial compound. In vivo follow-up studies are 
necessary to provide data in this regard. Nevertheless, in 
a preventive set-up, no cells are present immediately after 
implant installation when infections are most common 
to occur. When compounds should be administered for 
Fig. 8. Prevention of C. albicans biofilm formation 
on chlorhexidine-releasing Ti/SiO2 disks. Different 
concentrations of chlorhexidine were applied to the 
feed reservoir in the in vitro test tool. Values are mean 
metabolic activity of 72 h old C. albicans biofilms 
± standard error (n = 3), measured by CTB staining. The 
asterisks indicate a statistically significant difference in 
metabolic activity (** p < 0.01).
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curative reasons, the infection is often associated with 
bone loss which will (re-)enable release of compounds.
Britt Wildermann: Information regarding the mechanical 
properties would be interesting. Do these implants fulfil 
the requirements of dental implants?
Authors: This important issue will need to be explored 
in order to take the current proof of concept further to 
a potential clinical implementation. The presence of 
micropores in the titanium implant will inherently reduce 
its mechanical strength, while fatigue cracks can initiate 
at the open surface pores reducing its endurance limit. 
However, it is not well understood how the presence of a 
second phase (SiO2) inside the micropores will influence 
the mechanical behaviour of the composite material. 
Therefore, future work will focus on the characterisation 
of the mechanical properties of the designed implants.
Reto Luginbuehl: Do you have data on blocking of the 
pores by adsorbed proteins or calcification?
Authors: The pores of the silica correspond to the 
void volumes generated by crosslinking of spherical 
nanoparticles. The 3D porous network facilitates 
molecular transport and minimises the risk of pore 
blockage, especially for relatively smaller molecules like 
chlorhexidine. Currently, there is no data available on 
how the adsorption of macromolecules/proteins (from the 
implant environment) or bone formation on the implants 
outer surface will influence the controlled release of the 
bioactive target molecules (such as the chlorhexidine 
used in this study). The controlled release is a diffusion 
process driven by a concentration difference of the target 
molecule between the internal reservoir and the implant 
surroundings. We anticipate that the presence of proteins or 
bone on the implant surface will slow down the dissipation 
of the target molecule and lead to a local build-up. As such, 
the driving force for the diffusion through the implant will 
be less. However, when infections occur, this is usually 
accompanied by bone loss, so that the concentration of the 
target molecule at the implant surface will drop again, in 
turn increasing the release from the implant.
T. Fintan Moriarty: Does the internal cavity/reservoir 
refill with physiological fluids after antimicrobials have 
released? Presumably, the release of antibiotic will not 
result in a vacuum within the implant and if the reservoir 
can be refilled with fluid entering between the cover screw 
and implant, could the reservoir also become colonised by 
oral microflora?
Authors: Indeed, we hypothesise that release of the 
antimicrobial agent from the reservoir will not result in a 
vacuum, but will probably allow water molecules (which 
can migrate through the mesopores) to migrate to the 
cavity. However, this will not be possible for the microbial 
cells as these are too big (approx. 0.2-1 µm micro-organism 
size versus 6 nm pore size). As indicated in the Materials 
and Methods section, we used a stainless steel cover screw 
(M2 × 2.25) for flexible refilling of the internal reservoir. 
This cover screw is equipped with a conical surface mating 
the 2° countersink in the implant abutment in order to 
provide a sealing surface that effectively prevents leakage 
of the drug solution to the oral cavity and vice versa. Hence, 
we do not anticipate that fluid can enter the cavity through 
the cover screw.
Editor’s note: The Scientific Editor responsible for this 
paper was T. Fintan Moriarty.
